Abstract
Honokiol (3’,5-di-(2-propenyl)-1,1’-biphenyl-2,4’-diol) is a bioactive natural product derived from Magnolia spp. Recent studies have demonstrated anti-inflammatory, anti-angiogenic, anti-oxidative and anticancer properties of honokiol in vitro and in preclinical models. Honokiol targets multiple signaling pathways including nuclear factor kappa B (NF-κB), signal transducers and activator of transcription 3 (STAT3), epidermal growth factor receptor (EGFR) and mammalian target of rapamycin (m-TOR), which have great relevance during cancer initiation and progression. Furthermore, pharmacokinetic profile of honokiol has revealed a desirable spectrum of bioavailability after intravenous administration in animal models, thus making it a suitable agent for clinical trials. In this review, we discuss recent data describing the molecular targets of honokiol and its anti-cancer activities against various malignancies in pre-clinical models. Evaluation of honokiol in clinical trials will be the next step towards its possible human applications.
Keywords: Honokiol, chemoprevention, chemotherapy, natural agent, Magnolia, traditional Chinese medicine, cancer, aspirin, taxol, natural products, anti-tumor activity, carcinoma, cytotoxicity, human myelogenous leukemia, adenocarcinoma
Current Molecular Medicine
Title:Honokiol: A Novel Natural Agent for Cancer Prevention and Therapy
Volume: 12 Issue: 10
Author(s): S. Arora, S. Singh, G.A. Piazza, C.M. Contreras, J. Panyam and A.P. Singh
Affiliation:
Keywords: Honokiol, chemoprevention, chemotherapy, natural agent, Magnolia, traditional Chinese medicine, cancer, aspirin, taxol, natural products, anti-tumor activity, carcinoma, cytotoxicity, human myelogenous leukemia, adenocarcinoma
Abstract: Honokiol (3’,5-di-(2-propenyl)-1,1’-biphenyl-2,4’-diol) is a bioactive natural product derived from Magnolia spp. Recent studies have demonstrated anti-inflammatory, anti-angiogenic, anti-oxidative and anticancer properties of honokiol in vitro and in preclinical models. Honokiol targets multiple signaling pathways including nuclear factor kappa B (NF-κB), signal transducers and activator of transcription 3 (STAT3), epidermal growth factor receptor (EGFR) and mammalian target of rapamycin (m-TOR), which have great relevance during cancer initiation and progression. Furthermore, pharmacokinetic profile of honokiol has revealed a desirable spectrum of bioavailability after intravenous administration in animal models, thus making it a suitable agent for clinical trials. In this review, we discuss recent data describing the molecular targets of honokiol and its anti-cancer activities against various malignancies in pre-clinical models. Evaluation of honokiol in clinical trials will be the next step towards its possible human applications.
Export Options
About this article
Cite this article as:
Arora S., Singh S., Piazza G.A., Contreras C.M., Panyam J. and Singh A.P., Honokiol: A Novel Natural Agent for Cancer Prevention and Therapy, Current Molecular Medicine 2012; 12 (10) . https://dx.doi.org/10.2174/156652412803833508
DOI https://dx.doi.org/10.2174/156652412803833508 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Thyroid Hormone-Induced Angiogenesis
Current Cardiology Reviews The Application of Connected QSRR and QSAR Strategies to Predict the Physicochemical Interaction of Acridinone Derivatives with DNA
Combinatorial Chemistry & High Throughput Screening Oxidative Stress and Neurodegenerative Diseases: A Neurotrophic Approach
Current Drug Targets Photosensitizers Mediated Photodynamic Inactivation Against Virus Particles
Mini-Reviews in Medicinal Chemistry Prostate-Apoptosis-Response-Gene-4: Biological Properties and their Potential Therapeutic Exploitation in Hematological Malignancies
Letters in Drug Design & Discovery CoMFA/CoMSIA and Molecular Docking Studies of Novel Matrix Metalloproteinase- 2 Inhibitors Based on L-tyrosine Scaffold
Letters in Drug Design & Discovery Recent Advances in T Cell Adoptive Immunotherapy of Cancer
Current Cancer Therapy Reviews Linking Fold, Function and Phylogeny: A Comparative Genomics View on Protein (Domain) Evolution
Current Genomics Genetics of Obesity: What have we Learned?
Current Genomics Synthesis, DNA Binding Ability and Anticancer Activity of 2-heteroaryl Substituted Benzimidazoles Linked Pyrrolo[2,1-c][1,4]benzodiazepine Conjugates
Medicinal Chemistry Recent Progress in the Design and Discovery of RXR Modulators Targeting Alternate Binding Sites of the Receptor
Current Topics in Medicinal Chemistry Meet Our Editorial Board Member
The Natural Products Journal Tropism-Modified Adenoviral and Adeno-Associated Viral Vectors for Gene Therapy
Current Gene Therapy Cannabinoids
Current Drug Targets - CNS & Neurological Disorders Mitochondrial Generation of Reactive Oxygen Species and its Role in Aerobic Life
Current Medicinal Chemistry miR-1271 Regulates Cisplatin Resistance of Human Gastric Cancer Cell Lines by Targeting IGF1R, IRS1, mTOR, and BCL2
Anti-Cancer Agents in Medicinal Chemistry Molecular Targets of the Oncogenic Transcription Factor Jun
Current Cancer Drug Targets Colorectal Cancer Chemotherapy: The Evolution of Treatment and New Approaches
Current Medicinal Chemistry Potential Deployment of Angiotensin I Converting Enzyme Inhibitors and of Angiotensin II Type 1 and Type 2 Receptor Blockers in Cancer Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Advances in the Anticancer Value of the Ursolic Acid Through Nanodelivery
Current Medicinal Chemistry